Chemogenomic Analysis Identifies Geldanamycins As Substrates and Inhibitors of ABCB1

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2007 Apr 26

PMID 17457659

Citations 7

Authors

Ying Huang

Paul E Blower

Ruqing Liu

Zunyan Dai

Anh-Nhan Pham

Hojin Moon

Jialong Fang

Wolfgang Sadee

Affiliations

Soon will be listed here.

Abstract

Purpose: A prerequisite for geldanamycin (GA, NSC122750) to targeting heat shock protein 90 and inhibiting tumor growth is sufficient intracellular drug accumulation. We hypothesized that membrane transporters on tumor cells determine at least in part the response to GA analogues.

Materials And Methods: To facilitate a systematic study of chemosensitivity across a group of GA analogues with similar chemical structures, we correlated mRNA expression profiles of most known transporters with growth inhibitory potencies of compounds in 60 tumor cell lines (NCI-60). We subsequently validated the gene-drug correlations using cytotoxicity and transport assays.

Results: Geldanamycin analogues displayed a range of negative correlations coefficients with ABCB1 (MDR1, or P-glycoprotein) expression. Suppressing ABCB1 in multidrug resistant cells (NCI/ADR-RES and K562/DOX) and ABCB1-transfected cells (BC19) increased sensitivity to GA analogues, as expected for substrates. Moreover, ABCB1-mediated efflux of daunorubicin in K562/DOX cells could be blocked markedly by GA analogues in a dose-dependent fashion. The IC(50) values (half-maximum inhibition of daunorubicin efflux) were 5.5, 7.3 and 12 muM for macbecin II (NSC330500), 17-AAG (NSC330507) and GA, respectively.

Conclusions: These observations demonstrate that GA analogues are substrates as well as inhibitors of ABCB1, suggesting that drug interactions between GA analogues and other agents that are ABCB1 substrates may occur via ABCB1 in normal or tumor cells.

Citing Articles

Heat Shock Protein Inhibitor 17-Allyamino-17-Demethoxygeldanamycin, a Potent Inductor of Apoptosis in Human Glioma Tumor Cell Lines, Is a Weak Substrate for ABCB1 and ABCG2 Transporters.

Pastvova N, Dolezel P, Mlejnek P Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33573093 PMC: 7912456. DOI: 10.3390/ph14020107.

Prioritization of Transporter-Drug Relationships From Drug Sensitivity Screens.

Cesar-Razquin A, Girardi E, Yang M, Brehme M, Saez-Rodriguez J, Superti-Furga G Front Pharmacol. 2018; 9:1011.

PMID: 30245630 PMC: 6137680. DOI: 10.3389/fphar.2018.01011.

Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.

Grieve S, Gao Y, Hall C, Hu J, Greer P Mol Cell Biol. 2016; 36(15):2078-88.

PMID: 27215381 PMC: 4946432. DOI: 10.1128/MCB.01062-15.

Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2.

Van Hauwenhuyse F, Fiori A, Van Dijck P Eukaryot Cell. 2014; 13(10):1278-89.

PMID: 25084864 PMC: 4187652. DOI: 10.1128/EC.00096-14.

A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.

Broccatelli F, Carosati E, Neri A, Frosini M, Goracci L, Oprea T J Med Chem. 2011; 54(6):1740-51.

PMID: 21341745 PMC: 3069647. DOI: 10.1021/jm101421d.

References

Huang Y, Sadee W . Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2005; 239(2):168-82. DOI: 10.1016/j.canlet.2005.07.032. View

Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D . New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82(13):1107-12. DOI: 10.1093/jnci/82.13.1107. View

Smith V, Sausville E, Camalier R, Fiebig H, Burger A . Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol. 2005; 56(2):126-37. DOI: 10.1007/s00280-004-0947-2. View

Hamada A, Miyano H, Watanabe H, Saito H . Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. 2003; 307(2):824-8. DOI: 10.1124/jpet.103.055574. View

Weinstein J, Myers T, OConnor P, Friend S, Fornace Jr A, Kohn K . An information-intensive approach to the molecular pharmacology of cancer. Science. 1997; 275(5298):343-9. DOI: 10.1126/science.275.5298.343. View

Egorin M, Rosen D, WOLFF J, Callery P, Musser S, Eiseman J . Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998; 58(11):2385-96. View

Marie J, Zhou D, Zittoun R . Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia. 1993; 7(6):825-31. View

Gottesman M, Pastan I . Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993; 62:385-427. DOI: 10.1146/annurev.bi.62.070193.002125. View

Kajiji S, Dreslin J, Grizzuti K, Gros P . Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochemistry. 1994; 33(17):5041-8. DOI: 10.1021/bi00183a006. View

10.

Baselga J, Arteaga C . Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005; 23(11):2445-59. DOI: 10.1200/JCO.2005.11.890. View

11.

Huang Y, Anderle P, Bussey K, Barbacioru C, Shankavaram U, Dai Z . Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004; 64(12):4294-301. DOI: 10.1158/0008-5472.CAN-03-3884. View

12.

Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L . 17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther. 2003; 2(2):123-9. View

13.

Scala S, Akhmed N, Rao U, Paull K, Lan L, Dickstein B . P-glycoprotein substrates and antagonists cluster into two distinct groups. Mol Pharmacol. 1997; 51(6):1024-33. DOI: 10.1124/mol.51.6.1024. View

14.

Wacher V, Wu C, Benet L . Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995; 13(3):129-34. DOI: 10.1002/mc.2940130302. View

15.

Li D, Au J . Mdr1 transfection causes enhanced apoptosis by paclitaxel: an effect independent of drug efflux function of P-glycoprotein. Pharm Res. 2001; 18(7):907-13. DOI: 10.1023/a:1010919823936. View

16.

Riss T, Moravec R . Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev Technol. 2004; 2(1):51-62. DOI: 10.1089/154065804322966315. View

17.

Tian Z, Liu Y, Zhang D, Wang Z, Dong S, Carreras C . Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 2004; 12(20):5317-29. DOI: 10.1016/j.bmc.2004.07.053. View

18.

Scherf U, Ross D, Waltham M, Smith L, Lee J, Tanabe L . A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000; 24(3):236-44. DOI: 10.1038/73439. View

19.

Monks A, Scudiero D, Johnson G, Paull K, Sausville E . The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des. 1997; 12(7):533-41. View

20.

Goetz M, Toft D, Reid J, Ames M, Stensgard B, Safgren S . Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005; 23(6):1078-87. DOI: 10.1200/JCO.2005.09.119. View